Beaton Management Co. Inc. Buys New Shares in Eli Lilly and Company (NYSE:LLY)

Beaton Management Co. Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,700 shares of the company’s stock, valued at approximately $3,323,000. Eli Lilly and Company accounts for about 2.0% of Beaton Management Co. Inc.’s portfolio, making the stock its 15th largest position.

Other hedge funds have also recently made changes to their positions in the company. Buckhead Capital Management LLC boosted its holdings in Eli Lilly and Company by 0.7% during the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after buying an additional 15 shares in the last quarter. Levin Capital Strategies L.P. lifted its holdings in shares of Eli Lilly and Company by 3.8% in the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after purchasing an additional 15 shares in the last quarter. Clearwater Capital Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.3% in the fourth quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock valued at $701,000 after purchasing an additional 15 shares in the last quarter. JGP Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after purchasing an additional 16 shares in the last quarter. Finally, Valley Wealth Managers Inc. lifted its holdings in shares of Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after purchasing an additional 17 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $769.53.

Eli Lilly and Company Trading Down 0.0 %

Shares of Eli Lilly and Company stock traded down $0.35 during trading hours on Wednesday, hitting $802.82. The company’s stock had a trading volume of 1,766,155 shares, compared to its average volume of 3,005,803. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $816.61. The business has a fifty day moving average of $762.62 and a 200 day moving average of $689.24. The company has a market capitalization of $763.01 billion, a PE ratio of 117.74, a P/E/G ratio of 1.55 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the prior year, the business earned $1.62 earnings per share. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.